CO4750643A1 - Formulacion estable de la insulina que contiene l-arginina y protamina - Google Patents

Formulacion estable de la insulina que contiene l-arginina y protamina

Info

Publication number
CO4750643A1
CO4750643A1 CO98030641A CO98030641A CO4750643A1 CO 4750643 A1 CO4750643 A1 CO 4750643A1 CO 98030641 A CO98030641 A CO 98030641A CO 98030641 A CO98030641 A CO 98030641A CO 4750643 A1 CO4750643 A1 CO 4750643A1
Authority
CO
Colombia
Prior art keywords
human insulin
lis
group
arginin
protamine
Prior art date
Application number
CO98030641A
Other languages
English (en)
Spanish (es)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Bruce Hill Frank
Nmn Li Shun
Dawn Marie Rebhun
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4750643A1 publication Critical patent/CO4750643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CO98030641A 1997-06-13 1998-06-01 Formulacion estable de la insulina que contiene l-arginina y protamina CO4750643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5308997P 1997-06-13 1997-06-13

Publications (1)

Publication Number Publication Date
CO4750643A1 true CO4750643A1 (es) 1999-03-31

Family

ID=21981869

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98030641A CO4750643A1 (es) 1997-06-13 1998-06-01 Formulacion estable de la insulina que contiene l-arginina y protamina

Country Status (30)

Country Link
US (3) US6034054A (OSRAM)
EP (1) EP0884053B1 (OSRAM)
JP (1) JP2002504908A (OSRAM)
KR (1) KR100597500B1 (OSRAM)
CN (1) CN1293916C (OSRAM)
AR (1) AR012894A1 (OSRAM)
AT (2) ATE226088T1 (OSRAM)
AU (1) AU734781B2 (OSRAM)
BR (1) BR9810116B1 (OSRAM)
CA (1) CA2295140C (OSRAM)
CO (1) CO4750643A1 (OSRAM)
CZ (1) CZ299637B6 (OSRAM)
DE (2) DE69834956T2 (OSRAM)
DK (1) DK0884053T3 (OSRAM)
EA (1) EA002880B1 (OSRAM)
ES (2) ES2264713T3 (OSRAM)
HU (1) HUP0002877A3 (OSRAM)
ID (1) ID24310A (OSRAM)
IL (1) IL133348A0 (OSRAM)
NO (1) NO996131L (OSRAM)
NZ (1) NZ501382A (OSRAM)
PE (1) PE79099A1 (OSRAM)
PL (1) PL194244B1 (OSRAM)
PT (2) PT884053E (OSRAM)
SV (1) SV1998000065A (OSRAM)
TR (1) TR199903036T2 (OSRAM)
TW (1) TW577753B (OSRAM)
UA (1) UA61109C2 (OSRAM)
WO (1) WO1998056406A1 (OSRAM)
ZA (1) ZA984697B (OSRAM)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE60042550D1 (de) 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
CA2369451C (en) 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001052937A1 (en) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US20030199445A1 (en) * 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
KR101123113B1 (ko) * 2002-07-29 2012-03-15 쎄라피콘 에스.알.엘. 코 펩티드 약학 제형
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
CN101060856B (zh) * 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
EP2992902A1 (en) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Lipid complexes coated with peg and their uses
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
WO2006125763A1 (en) * 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE471144T1 (de) * 2005-10-20 2010-07-15 Mdrna Inc Intranasale verabreichung von schnell wirkendem insulin
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007135117A2 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8114428B2 (en) * 2007-03-08 2012-02-14 Sbf Synthetic Bone Factory Gmbh Methods for manufacturing a composition for treating bone and/or cartilage defects
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
WO2009133408A2 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
JP2012516342A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 結晶性インスリン複合体
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
EP2408470A4 (en) 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
PT2612677E (pt) * 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
EP2724739B1 (en) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Portable infusion pump system
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
EP2598170A4 (en) 2010-07-28 2016-07-06 Smartcells Inc MEDICINAL LIGANDEN CONJUGATES, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREOF
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102188367B (zh) * 2011-01-05 2012-11-07 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130345113A1 (en) * 2011-07-13 2013-12-26 Ronald E. Strohbehn Method of Use of Activated Functional Proteins to Improve Animal Health
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
ES2574761T3 (es) * 2011-10-31 2016-06-21 Xeris Pharmaceuticals, Inc. Formulaciones para el tratamiento de la diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
MX360420B (es) * 2012-12-19 2018-10-31 Wockhardt Ltd Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
BR112015013223A2 (pt) * 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
WO2015008169A2 (en) * 2013-07-04 2015-01-22 Insuline Medical Ltd. Device, system and method for delivery of a long-acting drug
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
CN112957455A (zh) * 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
EP3091965A1 (en) * 2014-01-09 2016-11-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR102351111B1 (ko) * 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105535942B (zh) * 2016-01-28 2017-07-28 通化东宝药业股份有限公司 一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
US20210187078A1 (en) * 2016-02-25 2021-06-24 Wockhardt Limited Pharmaceutical composition of insulin glargine and amino acids
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
US12065381B2 (en) 2019-07-11 2024-08-20 Skyworks Solutions, Inc. Temperature-stable, low-dielectric constant material with an ultra-low loss tangent
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
PH12023500012A1 (en) 2020-11-19 2024-03-11 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
US20240366731A1 (en) 2021-08-12 2024-11-07 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
CN119405787A (zh) * 2024-09-24 2025-02-11 广东东阳光生物制剂有限公司 一种高稳定性的高浓度含锌胰岛素制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1285023A (en) 1968-08-09 1972-08-09 Novo Terapeutisk Labor As Improvements in or relating to injectable insulin preparations
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS5767548A (en) * 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen

Also Published As

Publication number Publication date
HUP0002877A3 (en) 2001-03-28
CZ445199A3 (cs) 2000-07-12
CA2295140C (en) 2010-09-14
ES2264713T3 (es) 2007-01-16
BR9810116A (pt) 2000-08-08
TR199903036T2 (xx) 2000-06-21
SV1998000065A (es) 1999-02-03
PL194244B1 (pl) 2007-05-31
AU734781B2 (en) 2001-06-21
KR20010013700A (ko) 2001-02-26
US20030104983A1 (en) 2003-06-05
DE69808695T2 (de) 2003-06-12
BR9810116B1 (pt) 2009-05-05
ZA984697B (en) 1999-12-01
ES2185113T3 (es) 2003-04-16
DE69834956T2 (de) 2007-05-24
ID24310A (id) 2000-07-13
TW577753B (en) 2004-03-01
PT884053E (pt) 2002-12-31
EP0884053A1 (en) 1998-12-16
DE69834956D1 (de) 2006-07-27
NZ501382A (en) 2001-08-31
WO1998056406A1 (en) 1998-12-17
IL133348A0 (en) 2001-04-30
CN1293916C (zh) 2007-01-10
KR100597500B1 (ko) 2006-07-10
PL337324A1 (en) 2000-08-14
AU7837798A (en) 1998-12-30
DE69808695D1 (de) 2002-11-21
PE79099A1 (es) 1999-08-24
EA002880B1 (ru) 2002-10-31
CZ299637B6 (cs) 2008-10-01
EA200000014A1 (ru) 2000-06-26
JP2002504908A (ja) 2002-02-12
EP0884053B1 (en) 2002-10-16
US6551992B1 (en) 2003-04-22
PT1283051E (pt) 2006-08-31
NO996131L (no) 2000-02-03
DK0884053T3 (da) 2002-11-04
UA61109C2 (uk) 2003-11-17
CA2295140A1 (en) 1998-12-17
US6034054A (en) 2000-03-07
ATE329612T1 (de) 2006-07-15
HUP0002877A2 (hu) 2001-01-29
NO996131D0 (no) 1999-12-10
CN1266371A (zh) 2000-09-13
US6906028B2 (en) 2005-06-14
ATE226088T1 (de) 2002-11-15
HK1030747A1 (en) 2001-05-18
AR012894A1 (es) 2000-11-22

Similar Documents

Publication Publication Date Title
SV1998000065A (es) Formulas estables de insulina ref. x-10675
CO4410203A1 (es) Formulaciones de analogos de insulina
CO4410204A1 (es) Formulaciones de analogos de insulina monomericos
UY25791A1 (es) Combinaciones para la diabetes
ATE220920T1 (de) Stickstoffoxydabgebendes präparat zur reduzierung der toxizität von wirkstoffen
PE20000106A1 (es) Composiciones insolubles para controlar la glucosa en la sangre
BRPI0208210B8 (pt) preparação de insulina pobre em zinco e isenta de zinco com estabilidade aperfeiçoada
AR015899A1 (es) Derivado de insulina o sales compatibles de los mismos, procedimiento para su preparacion, secuencias de adn, vector de expresion, celula hospedante incapaz de conducir a la regeneracion de un animal o planta, composicion farmaceutica, solucion inyectable con actividad de insulina y utilizacion de d
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
DK0613683T3 (da) Anvendelse af erythropoietin til fremstilling af et farmaceutisk præparat til pulmonal administration eller inhalation
ES2038088A6 (es) Dispositivo administrador autoinyectador para suministrar sustancias farmaceuticas.
DK0431456T3 (da) Anvendelse af et tungtopløseligt salt af en heteropolysyre til bestemmelse af en analyt, tilsvarende fremgangsmåde til bestemmelsen samt hertil egnet middel
PE20040560A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
AR038927A1 (es) Sales de acido organico
ES2111102T3 (es) Formulaciones cosmeticas y dermatologicas con un contenido activo en acido cis-urocaninico.
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
BR9810711A (pt) Formulação tópica de pulverização antipruriginosa, e, processo para prevenção ou tratamento de prurido em um paciente
PT95212A (pt) Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion
ECSP982525A (es) Formulaciones estables de insulina
ES2012573A6 (es) Una composicion fungicida activa en el control de hongos fitopatogenos, en particular oomicetos.
ATE416763T1 (de) Photostabilisierte topische formulierungen von ketoprofen mit zwei uv-filtern
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
NO920255L (no) Podofyllotoksinpreparat som inneholder triglyserider
ATE225653T1 (de) Neomycin/disaccharid wässerige lösung zur behandlung von enteroclysis bei hepatischer enzephalopathie